Physician profile
Nicholas Benner
NPI 1316268618
$356,230.83
in general payments reported to CMS, 2019-2025
38 companies · $105K in 2025
The $105K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $33K · 2021: $35K · 2022: $44K · 2023: $73K · 2024: $46K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Food and Beverage: $14K · Travel and Lodging: $10K · Education: $338 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,078.00 |
| Food and Beverage | $14,100.24 |
| Travel and Lodging | $10,476.07 |
| Education | $337.52 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $138,679.84 | 2019-2025 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $98,317.29 | 2019-2025 | Aklief, Epsolay, Oracea |
| Janssen Scientific Affairs, LLC | $45,842.91 | 2021-2022 | |
| Abbvie INC. | $36,409.27 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $12,520.45 | 2019-2025 | |
| Genzyme Corporation | $6,754.32 | 2019-2025 | |
| Journey Medical Corporation | $6,573.45 | 2019-2025 | |
| Dermira, INC. | $3,781.04 | 2019-2020 | |
| Lilly USA, LLC | $1,130.56 | 2019-2025 | Ebglyss, Taltz |
| Almirall LLC | $969.09 | 2019-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $840.99 | 2023-2024 | Vtama |
| Pfizer INC. | $796.20 | 2019-2025 | |
| Ucb, INC. | $630.63 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $599.74 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $426.96 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.